Anti-PD-L1 antibody for detecting PD-L1

Patent metadata

Field	Value
Publication number	US-10865246-B2
Application number	US-201816491145-A
Country	US
Kind code	B2
Filing date	Mar 23, 2018
Priority date	Mar 27, 2017
Publication date	Dec 15, 2020
Grant date	Dec 15, 2020

Abstract

An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDF (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.

First claim

The invention claimed is:

1. An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDF (SEQ ID NO: 5).

2. The antibody of claim 1 , which is from rat.

3. The antibody of claim 2 , which is a rat anti-bovine PD-L1 antibody.

4. The antibody of claim 3 , wherein the light chain variable region has the amino acid sequence as shown in SEQ ID NO. 6 and the heavy chain variable region has the amino acid sequence as shown in SEQ ID NO: 7.

5. The antibody of claim 1 , wherein the light chain constant region has the amino acid sequence of the constant region of kappa chain.

6. The antibody of claim 1 , wherein the heavy chain constant region has the amino acid sequence of the constant region of IgG2a.

7. The antibody of claim 5 , wherein the light chain constant region has the amino acid sequence as shown in any one of SEQ ID NOS: 8, 10 to 12 and the heavy chain constant region has the amino acid sequence as shown in SEQ ID NO: 9 or 13.

8. The antibody of claim 1 which has a four-chain structure comprising two light chains and two heavy chains.

9. A composition comprising the antibody of claim 1 as an active ingredient and a carrier.

10. A method to diagnose malignant melanoma cancer comprising contacting in vitro one or more cells from a subject with the composition of claim 9 ; determining if said antibodies in said composition binds to said one or more cells, wherein increased binding to cancer cell as compared to a control is indicative of malignant melanoma cancer.

Assignees

• Fuso Pharmaceutical Ind
• Univ Hokkaido Nat Univ Corp

Inventors

• KONNAI Satoru
• Ohashi Kazuhiko
• Murata Shiro
• Okagawa Tomohiro
• Nishimori Asami
• Maekawa Naoya
• Takagi Satoshi
• Kagawa Yumiko
• Suzuki Yasuhiko
• Nakajima Chie

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/575

  for cancer · CPC title

• C07K16/2827 Primary

  against B7 molecules, e.g. CD80, CD86 · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• G01N33/53

  Immunoassay; Biospecific binding assay; Materials therefor · CPC title